$\square$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

							<u> </u>		e invesimer			011340								
	nd Address of EN MAR		2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>SURMODICS INC</u> [ SRDX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner									
(Last) (First) (Middle) 9924 WEST 74TH STREET							3. Date of Earliest Transaction (Month/Day/Year) 01/26/2004								X Officer (give title Other (specify below) below) Vice President					
(Street) EDEN PRAIRIE MN 55344						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(City) (State) (Zip)															Form filed by More than One Reporting Person					
		Tab	le I - Noi	ו-Deri	vative	e Sec	curitie	s A	cquired,	Dis	posed o	of, or Be	neficia	lly Owne	d					
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date			e, Transaction Disp Code (Instr. 5)			ities Acquir d Of (D) (Ins		Benefic	ies ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) o (D)	r Price	Transad	action(s) 3 and 4)			(Instr. 4)			
Common Stock														39	9,514		D			
		٢							quired, D s, optior			,		y Owned						
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, T rity or Exercise (Month/Day/Year) if any C		4. Transa Code ( 8)		n of I		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		e S Ily J	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares							
Employee Stock Option (Right to Buy)	\$3.875								(1)	0!	9/21/2005	Common Stock	5,000		5,000	)	D			
Employee Stock Option (Right to Buy)	\$8.0625								(2)	0	9/20/2006	Common Stock	16,000		16,00	0	D			
Employee Stock Option (Right to Buy)	\$25.094								(3)	0	9/18/2007	Common Stock	12,000		12,00	0	D			
Employee Stock												Common								

(4)

(5)

5,000

Α

Explanation of Responses:

\$29.17

\$21.36

1. Exercisable in annual increments of 1,000 shares each commencing 9/21/99.

2. Exercisable in annual increments of 3,200 shares each commencing 9/20/00.

01/26/2004

3. Exercisable in annual increments of 2,400 shares each commencing 9/18/01.

4. Exercisable in annual increments of 1,600 shares each commencing 3/17/04.

5. Exercisable in annual increments of 1,000 shares each commencing 1/26/05.

**Remarks:** 

Option

(Right to Buy) Non-Qualified Stock

Option (Right to Buy)

Marie J. Versen by Philip D. Ankeny pursuant to power of attorney filed herewith \*\* Signature of Reporting Person

Common

Stock

Common

Stock

03/17/2010

01/26/2011

8,000

5,000

\$<mark>0</mark>

01/29/2004

Date

8,000

5,000

D

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned hereby constitutes and appoints Philip D. Ankeny, David C. Grorud and Melodie R. Rose ("Attorney-in-Fact"), or any one of them acting alone, the undersigned's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any or all Forms 4 or Forms 5 relating to beneficial ownership of securities of SurModics (the "Issuer"), to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to deliver a copy of the same to the Issuer, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in effect until such time as the undersigned is no longer subject to the provisions of Section 16 of the Securities Exchange Act of 1934 with respect to securities of the Issuer or until this Power of Attorney is replaced by a later dated Power of Attorney or revoked by the undersigned in writing.

The undersigned hereby indemnifies the Attorneys-in-Fact for all losses and costs the Attorneys-in-Fact may incur in connection with or arising from the Attorneys-in-Fact's execution of their authorities granted hereunder.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of November, 2003.

/s/ Marie J. Versen Marie J. Versen